Cue Biopharma Inc (CUE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$30.50+1.67%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Cue Biopharma is working on important clinical goals for CUE-221 and CUE-401. It has a license deal with Ascendant Health Sciences. The company also has a partnership with Boehringer Ingelheim. These moves could help it grow despite current losses.
The company is losing money and revenue is expected to drop sharply. Four board members resigned recently. New CEO changes add uncertainty. These issues could hurt progress and value.
The market expects about a 90% drop in revenue. Our fair value is near $85, showing the stock is cheap versus peers. We see some chance for recovery but risks remain high.
Breaks if: Failure to advance clinical milestones for CUE-221 and CUE-401 by FY26
Breaks if: License agreement with Ascendant Health Sciences fails or stalls by FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CUE represents a speculative growth investment. The company is focused on advancing its clinical milestones while navigating a volatile management landscape and weak financial performance.
The market currently prices CUE as a cheap option compared to its peers, with a slight expectations gap. This suggests that investors may have low expectations for immediate performance, given the company's recent struggles.
Fundamentally, CUE is on track with its clinical milestones, but recent financial performance has been weak. The company has shown some revenue growth, but it remains loss-making, which adds to the risk profile.
The thesis hinges on several factors, including the company's ability to meet clinical milestones and the overall health of the healthcare sector. Additionally, guidance changes and economic indicators, such as job reports, could significantly impact investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates a decline in the reasons to own the company. The market has not reacted strongly, with only a muted price movement.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Additional major board resignations or CEO departures in 2026
Breaks if: No progress in compound selection or lead optimization by FY26
Over the next 1 to 3 years, CUE's prospects will depend on its clinical advancements and the broader economic environment. Not investment advice.